FDA reminds asthma sufferers to inhale capsules, not swallow them

ROCKVILLE, Md. The Food and Drug Administration on Friday issued a Public Health Advisory on the correct use of Spiriva and Foradil capsules, capsules designed to be inhaled through either a Spiriva HandiHaler or Foradil Aerolizer inhalation device, respectively, to improve breathing in patients with asthma, and in individuals affected by chronic obstructive lung disease, including chronic bronchitis and emphysema.

FDA has received reports that some consumers are swallowing the capsules. “[And] while the reports indicate that few patients experienced side effects from swallowing the capsules, it is important to note that Spiriva or Foradil will not treat a patient’s breathing condition if the capsules are swallowed rather than inhaled,” the FDA stated.

Health care professionals should discuss with patients how to correctly use the Spiriva HandiHaler or Foradil Aerolizer, FDA advised. Patient information includes highlighted statements noting that the capsule contents are to be inhaled and not swallowed. The FDA will continue to monitor reports of the incorrect use of these medications and, as needed, will continue to work with the manufacturers to improve the medications’ labeling and promote patient education for the correct use of these medications.